{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tesamorelin-muscle-loss","title":"Tesamorelin for Muscle Loss: Human Evidence on Lean Mass, Muscle Density, and the GH Axis","body":"## What's breaking down\nMuscle loss, or sarcopenia-like decline, often stems from reduced growth hormone (GH) signaling with age or illness. This lowers IGF-1, slowing protein synthesis while catabolic processes continue. Visceral fat accumulation adds mechanical and inflammatory stress that can further impair muscle quality. In HIV-related lipodystrophy, excess abdominal fat pairs with muscle fat infiltration and reduced lean area. Repair pathways lag behind breakdown when GH pulses weaken. Tesamorelin is discussed here because studies examine its effect on the GH axis and downstream tissue changes rather than symptom masking.\n\n## Why Tesamorelin might help you\nIf your muscle loss involves low GH/IGF-1 activity or excess visceral fat, the logic chain runs like this. Tesamorelin stimulates the pituitary to release endogenous GH in a more physiologic pattern. That raises circulating IGF-1. Higher IGF-1 supports protein synthesis in muscle tissue. In people who respond with visceral fat reduction, CT scans showed measurable gains in trunk muscle density and lean muscle area over 26 weeks. Therefore, if visceral fat or poor muscle quality is part of your profile, the compound is studied for its potential to shift the balance toward tissue-level repair signals instead of only lowering fat mass.\n\nStep 1: GH release increases. Step 2: IGF-1 rises in a pulsatile way. Step 3: Muscle protein turnover favors synthesis. Step 4: In responders, muscle fat decreases and lean area increases on imaging. This targets the regenerative side of the equation for the layers listed above.\n\n## How these fit together\nSingle-compound focus. Tesamorelin maps directly to the GH axis and visceral fat layer. If your situation includes multiple degeneration layers, this agent addresses the endocrine and body-composition component. Other approaches would need separate evaluation for neural, sleep, or direct anabolic layers.\n\n## What the evidence actually shows\nHuman data come from secondary analyses of randomized trials in adults with HIV and abdominal obesity. One key study (Adrian et al.) restricted analysis to tesamorelin responders who lost at least 8% visceral adipose tissue. Compared with placebo, these participants showed statistically significant increases in muscle density (1.56–4.86 Hounsfield units across trunk muscle groups) and lean muscle area (0.64–1.08 cm²). A later meta-analysis reported a mean lean body mass increase of 1.42 kg. An ongoing trial (NCT06554717) is testing tesamorelin plus exercise for physical function in HIV. No large human trials exist for primary sarcopenia in non-HIV populations. Animal data on muscle-specific outcomes with tesamorelin are not prominent in the reviewed sources. Reddit and X reports remain anecdotal.\n\n## What scientists say\nThe authors of the 2019 Journal of Frailty & Aging paper conclude that among responders, tesamorelin increased skeletal muscle area and density. They note the changes occurred alongside visceral fat reduction and call for longer-term studies on functional impact outside HIV. Reviews emphasize that lean mass gains occur without proportional subcutaneous fat loss or major glycemic disruption in the studied cohorts. Researchers highlight that benefits appear tied to visceral fat responders rather than universal.\n\n## What people say on Reddit\nUsers in peptide communities describe tesamorelin as helping preserve lean mass during calorie deficits. One post states: “Tesa is a tool that raises IGF-1 levels which can in turn preserves muscle mass in a calories deficit and potentially build lean muscle.” Another reports: “Even with zero exercise my lean muscle mass increased by about 15%, visceral fat reduction by 80%.” Several mention better recovery and visible muscle definition when combined with training, though scale weight often stays stable because fat loss offsets any lean gain. Experiences vary; some note waist reduction without overall weight change.\n\n## What people say on X\nPublic posts on X referencing tesamorelin and muscle are sparse in current searches. Most discussion echoes the clinical focus on visceral fat reduction and secondary lean mass observations from the HIV trials. Anecdotal functional claims appear less frequently than on Reddit.\n\n## What we do not know\nHuman evidence is concentrated in HIV populations with abdominal obesity. Direct trials in age-related sarcopenia or non-HIV muscle loss are absent. Long-term (>26 weeks) effects on muscle strength, physical performance, or fracture risk remain unmeasured in published data. Whether gains persist after stopping treatment is unknown. Interactions with resistance training protocols or other body-composition interventions need further controlled study. Effects on muscle in women or diverse ethnic groups are underrepresented.\n\n## Safety and limits\nReported adverse events in trials include injection-site reactions, arthralgia, myalgia, and paresthesia. No major glucose dysregulation appeared in the meta-analysis. Human data are limited to specific responder subgroups and short-to-medium durations. Individual responses differ, and imaging changes do not automatically equal improved daily function. All observations come from controlled settings; real-world variability is higher.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin-muscle-loss/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"In a secondary analysis of randomized trials, tesamorelin responders (visceral fat loss ≥8%) showed greater increases in trunk muscle density (1.56–4.86 HU) and lean muscle area (0.64–1.08 cm²) vs placebo after 26 weeks.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Provides direct human imaging evidence linking tesamorelin response to muscle quality changes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Meta-analysis of tesamorelin trials reported a mean lean body mass increase of 1.42 kg alongside visceral fat reduction.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Quantifies lean mass effect across studies in the target population.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"An ongoing clinical trial (NCT06554717) is evaluating tesamorelin plus exercise for physical function and muscle health in adults with HIV.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Indicates active research extending beyond fat loss to function.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report lean mass preservation or modest gains alongside visceral fat loss when using tesamorelin in calorie deficits, often with improved recovery.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4","s5"],"source_status":"sourced","why_material":"Captures real-user perceptions separate from trial data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31237318/","title":"The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV","quote":"tesamorelin was effective in increasing skeletal muscle area and density","summary":"Secondary analysis of two RCTs; CT-based muscle metrics in responders.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.507Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"b0762e1a20bcb7cab143fe210ef8291514be54fde7f370f5f92e0a7c6dd854c0"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"A meta-analysis of randomized controlled trials","quote":"A significant increase in lean body mass was observed (MD=1.42 kg, 95% CI [1.13, 1.71]; P < 0.001)","summary":"Pooled body composition outcomes from tesamorelin trials in HIV lipodystrophy.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.507Z","link_status":"ok","quote_status":"unverified","prev":"b0762e1a20bcb7cab143fe210ef8291514be54fde7f370f5f92e0a7c6dd854c0","hash":"96428706c2883c39545e36d3041e878f23e861dc3101a3979c9723c8946bcb5a"},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06554717","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function and Muscle Health in Adults With HIV","quote":"learn whether the medication tesamorelin will improve physical function and muscle health","summary":"Active trial combining tesamorelin with exercise.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.507Z","link_status":"ok","quote_status":"unverified","prev":"96428706c2883c39545e36d3041e878f23e861dc3101a3979c9723c8946bcb5a","hash":"3efea45c7c0c600b6dafd5b208d79dac941b37d97678691fa9d6c0281bc2e738"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/USPeptides/comments/1p3bh79/tesamorelin_belly_fat_reduction_growth_hormone/","title":"Tesamorelin Belly Fat Reduction","quote":"Tesa is a tool that raises IGF-1 levels which can in turn preserves muscle mass in a calories deficit","summary":"User discussion on muscle preservation.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.507Z","link_status":"ok","quote_status":"unverified","prev":"3efea45c7c0c600b6dafd5b208d79dac941b37d97678691fa9d6c0281bc2e738","hash":"29bc4fe1e1f6416bf82182800cddf3d1d1a998010ac69696096d1fa77afd898a"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1qlnwf7/starting_tesamorelin_next_week_advice_needed/","title":"Starting Tesamorelin","quote":"Even with zero exercise my lean muscle mass increased by about 15%","summary":"Self-reported body composition changes.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.507Z","link_status":"ok","quote_status":"unverified","prev":"29bc4fe1e1f6416bf82182800cddf3d1d1a998010ac69696096d1fa77afd898a","hash":"500a99f3722c7580a8a5679617ef7f79b2f3e68ec2b52837a913d9e8591d5e60"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:19:00.263Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Muscle Loss: Human Evidence on Lean Mass, Muscle Density, and the GH Axis","register":"source_ledger","body":"## What's breaking down\nMuscle loss, or sarcopenia-like decline, often stems from reduced growth hormone (GH) signaling with age or illness. This lowers IGF-1, slowing protein synthesis while catabolic processes continue. Visceral fat accumulation adds mechanical and inflammatory stress that can further impair muscle quality. In HIV-related lipodystrophy, excess abdominal fat pairs with muscle fat infiltration and reduced lean area. Repair pathways lag behind breakdown when GH pulses weaken. Tesamorelin is discussed here because studies examine its effect on the GH axis and downstream tissue changes rather than symptom masking.\n\n## Why Tesamorelin might help you\nIf your muscle loss involves low GH/IGF-1 activity or excess visceral fat, the logic chain runs like this. Tesamorelin stimulates the pituitary to release endogenous GH in a more physiologic pattern. That raises circulating IGF-1. Higher IGF-1 supports protein synthesis in muscle tissue. In people who respond with visceral fat reduction, CT scans showed measurable gains in trunk muscle density and lean muscle area over 26 weeks. Therefore, if visceral fat or poor muscle quality is part of your profile, the compound is studied for its potential to shift the balance toward tissue-level repair signals instead of only lowering fat mass.\n\nStep 1: GH release increases. Step 2: IGF-1 rises in a pulsatile way. Step 3: Muscle protein turnover favors synthesis. Step 4: In responders, muscle fat decreases and lean area increases on imaging. This targets the regenerative side of the equation for the layers listed above.\n\n## How these fit together\nSingle-compound focus. Tesamorelin maps directly to the GH axis and visceral fat layer. If your situation includes multiple degeneration layers, this agent addresses the endocrine and body-composition component. Other approaches would need separate evaluation for neural, sleep, or direct anabolic layers.\n\n## What the evidence actually shows\nHuman data come from secondary analyses of randomized trials in adults with HIV and abdominal obesity. One key study (Adrian et al.) restricted analysis to tesamorelin responders who lost at least 8% visceral adipose tissue. Compared with placebo, these participants showed statistically significant increases in muscle density (1.56–4.86 Hounsfield units across trunk muscle groups) and lean muscle area (0.64–1.08 cm²). A later meta-analysis reported a mean lean body mass increase of 1.42 kg. An ongoing trial (NCT06554717) is testing tesamorelin plus exercise for physical function in HIV. No large human trials exist for primary sarcopenia in non-HIV populations. Animal data on muscle-specific outcomes with tesamorelin are not prominent in the reviewed sources. Reddit and X reports remain anecdotal.\n\n## What scientists say\nThe authors of the 2019 Journal of Frailty & Aging paper conclude that among responders, tesamorelin increased skeletal muscle area and density. They note the changes occurred alongside visceral fat reduction and call for longer-term studies on functional impact outside HIV. Reviews emphasize that lean mass gains occur without proportional subcutaneous fat loss or major glycemic disruption in the studied cohorts. Researchers highlight that benefits appear tied to visceral fat responders rather than universal.\n\n## What people say on Reddit\nUsers in peptide communities describe tesamorelin as helping preserve lean mass during calorie deficits. One post states: “Tesa is a tool that raises IGF-1 levels which can in turn preserves muscle mass in a calories deficit and potentially build lean muscle.” Another reports: “Even with zero exercise my lean muscle mass increased by about 15%, visceral fat reduction by 80%.” Several mention better recovery and visible muscle definition when combined with training, though scale weight often stays stable because fat loss offsets any lean gain. Experiences vary; some note waist reduction without overall weight change.\n\n## What people say on X\nPublic posts on X referencing tesamorelin and muscle are sparse in current searches. Most discussion echoes the clinical focus on visceral fat reduction and secondary lean mass observations from the HIV trials. Anecdotal functional claims appear less frequently than on Reddit.\n\n## What we do not know\nHuman evidence is concentrated in HIV populations with abdominal obesity. Direct trials in age-related sarcopenia or non-HIV muscle loss are absent. Long-term (>26 weeks) effects on muscle strength, physical performance, or fracture risk remain unmeasured in published data. Whether gains persist after stopping treatment is unknown. Interactions with resistance training protocols or other body-composition interventions need further controlled study. Effects on muscle in women or diverse ethnic groups are underrepresented.\n\n## Safety and limits\nReported adverse events in trials include injection-site reactions, arthralgia, myalgia, and paresthesia. No major glucose dysregulation appeared in the meta-analysis. Human data are limited to specific responder subgroups and short-to-medium durations. Individual responses differ, and imaging changes do not automatically equal improved daily function. All observations come from controlled settings; real-world variability is higher.","claims":[{"id":"c1","text":"In a secondary analysis of randomized trials, tesamorelin responders (visceral fat loss ≥8%) showed greater increases in trunk muscle density (1.56–4.86 HU) and lean muscle area (0.64–1.08 cm²) vs placebo after 26 weeks.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Provides direct human imaging evidence linking tesamorelin response to muscle quality changes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Meta-analysis of tesamorelin trials reported a mean lean body mass increase of 1.42 kg alongside visceral fat reduction.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Quantifies lean mass effect across studies in the target population.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"An ongoing clinical trial (NCT06554717) is evaluating tesamorelin plus exercise for physical function and muscle health in adults with HIV.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Indicates active research extending beyond fat loss to function.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report lean mass preservation or modest gains alongside visceral fat loss when using tesamorelin in calorie deficits, often with improved recovery.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4","s5"],"source_status":"sourced","why_material":"Captures real-user perceptions separate from trial data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31237318/","title":"The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV","quote":"tesamorelin was effective in increasing skeletal muscle area and density","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"A meta-analysis of randomized controlled trials","quote":"A significant increase in lean body mass was observed (MD=1.42 kg, 95% CI [1.13, 1.71]; P < 0.001)","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06554717","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function and Muscle Health in Adults With HIV","quote":"learn whether the medication tesamorelin will improve physical function and muscle health","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/USPeptides/comments/1p3bh79/tesamorelin_belly_fat_reduction_growth_hormone/","title":"Tesamorelin Belly Fat Reduction","quote":"Tesa is a tool that raises IGF-1 levels which can in turn preserves muscle mass in a calories deficit","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1qlnwf7/starting_tesamorelin_next_week_advice_needed/","title":"Starting Tesamorelin","quote":"Even with zero exercise my lean muscle mass increased by about 15%","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":28916,"tokens_out":3094,"cost":0.04388,"prev_hash":"genesis","hash":"d531986ced9cab26dc5f9ff393cb4ce2acdedea1998974b4ef45145e7f6e6c8f"}],"provenance":[{"ts":"2026-06-29T23:19:00.263Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Muscle Loss\nSlug: tesamorelin-muscle-loss\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down\",\"Why Tesamorelin might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one pept","response":"{\n  \"slug\": \"tesamorelin-muscle-loss\",\n  \"title\": \"Tesamorelin for Muscle Loss: Human Evidence on Lean Mass, Muscle Density, and the GH Axis\",\n  \"body\": \"## What's breaking down\\nMuscle loss, or sarcopenia-like decline, often stems from reduced growth hormone (GH) signaling with age or illness. This lowers IGF-1, slowing protein synthesis while catabolic processes continue. Visceral fat accumulation adds mechanical and inflammatory stress that can further impair muscle quality. In HIV-related lipodystrophy, excess abdominal fat pairs with muscle fat infiltration and reduced lean area. Repair pathways lag behind breakdown when GH pulses weaken. Tesamorelin is discussed here because studies examine its effect on the GH axis and downstream tissue changes rather than symptom masking.\\n\\n## Why Tesamorelin might help you\\nIf your muscle loss involves low GH/IGF-1 activity or excess visceral fat, the logic chain runs like this. Tesamorelin stimulates the pituitary to release endogenous GH in a more physiologic pattern. That raises circulating IGF-1. Higher IGF-1 supports protein synthesis in muscle tissue. In people who respond with visceral fat reduction, CT scans showed measurable gains in trunk muscle density and lean muscle area over 26 weeks. Therefore, if visceral fat or poor muscle quality is part of your profile, the compound is studied for its potential to shift the balance toward tissue-level repair signals instead of only lowering fat mass.\\n\\nStep 1: GH release increases. Step 2: IGF-1 rises in a pulsatile way. Step 3: Muscle protein turnover favors synthesis. Step 4: In responders, muscle fat decreases and lean area increases on imaging. This targets the regenerative side of the equation for the layers listed above.\\n\\n## How these fit together\\nSingle-compound focus. Tesamorelin maps directly to the GH axis and visceral fat layer. If your situation includes multiple degeneration layers, this agent addresses the endocrine and body-composition component. Other","tokens_in":28916,"tokens_out":3094,"cost":0,"prev":"genesis","hash":"b893f8d91bcfbfd430c532f9f3d2c122415b4396cf0188fe404dfd7fcdea664f"},{"ts":"2026-07-17T02:42:24.087Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-muscle-loss","response":"19 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b893f8d91bcfbfd430c532f9f3d2c122415b4396cf0188fe404dfd7fcdea664f","hash":"19fbfa92b36bdaf0eb9f55164dc454f801ea701aad9e0d7c424975e61ff55919"}],"energy":{"passes":2,"tokens_in":28916,"tokens_out":3094,"tokens_total":32010,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"19fbfa92b36bdaf0eb9f55164dc454f801ea701aad9e0d7c424975e61ff55919"},"posted_at":"2026-06-29T21:33:33.546Z","created_at":"2026-06-29T21:33:33.546Z","updated_at":"2026-07-17T02:42:24.087Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin-muscle-loss","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin-muscle-loss","json":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss","bundle":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin-muscle-loss","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-muscle-loss\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-muscle-loss\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin-muscle-loss\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin-muscle-loss | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin-muscle-loss","json":"/api/articles/tesamorelin-muscle-loss","markdown":"/api/articles/tesamorelin-muscle-loss/bundle?format=markdown","skill":"/api/articles/tesamorelin-muscle-loss/skill","topology":"/api/articles/tesamorelin-muscle-loss/topology","versions":"/api/articles/tesamorelin-muscle-loss/revisions","invocations":"/api/articles/tesamorelin-muscle-loss/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin-muscle-loss","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"1fc7c99e0fb6ccfb9e96473b3ca8696008fab4fc7b0ebc642ebeaa71097037f0","object":{"object_type":"article-object","identity":{"id":"article:tesamorelin-muscle-loss","slug":"tesamorelin-muscle-loss","title":"Tesamorelin for Muscle Loss: Human Evidence on Lean Mass, Muscle Density, and the GH Axis"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tesamorelin-muscle-loss","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tesamorelin-muscle-loss/skill","role":"direct behavior","audience":"model","content":"---\nname: tesamorelin-muscle-loss\ndescription: Apply the Tesamorelin for Muscle Loss: Human Evidence on Lean Mass, Muscle Density, and the GH Axis article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Tesamorelin for Muscle Loss: Human Evidence on Lean Mass, Muscle Density, and the GH Axis\n\nThis Skill is the behavioral expression of [the canonical article](/a/tesamorelin-muscle-loss). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tesamorelin-muscle-loss.\n- Read claims and relationships at /api/articles/tesamorelin-muscle-loss/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Muscle loss, or sarcopenia-like decline, often stems from reduced growth hormone GH signaling with age or illness. This lowers IGF-1, slowing protein synthesis while catabolic processes continue. Visceral fat accumulati\n\n## Representations\n\n- Human: /a/tesamorelin-muscle-loss\n- JSON: /api/articles/tesamorelin-muscle-loss\n- Relationships: /api/articles/tesamorelin-muscle-loss/topology\n- History: /api/articles/tesamorelin-muscle-loss/revisions\n"},"json":{"route":"/api/articles/tesamorelin-muscle-loss","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tesamorelin-muscle-loss/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","tesamorelin","muscle","loss"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tesamorelin-muscle-loss/invocations?status=success","failure_events":"/api/articles/tesamorelin-muscle-loss/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tesamorelin-muscle-loss","title":"Tesamorelin for Muscle Loss: Human Evidence on Lean Mass, Muscle Density, and the GH Axis","body":"## What's breaking down\nMuscle loss, or sarcopenia-like decline, often stems from reduced growth hormone (GH) signaling with age or illness. This lowers IGF-1, slowing protein synthesis while catabolic processes continue. Visceral fat accumulation adds mechanical and inflammatory stress that can further impair muscle quality. In HIV-related lipodystrophy, excess abdominal fat pairs with muscle fat infiltration and reduced lean area. Repair pathways lag behind breakdown when GH pulses weaken. Tesamorelin is discussed here because studies examine its effect on the GH axis and downstream tissue changes rather than symptom masking.\n\n## Why Tesamorelin might help you\nIf your muscle loss involves low GH/IGF-1 activity or excess visceral fat, the logic chain runs like this. Tesamorelin stimulates the pituitary to release endogenous GH in a more physiologic pattern. That raises circulating IGF-1. Higher IGF-1 supports protein synthesis in muscle tissue. In people who respond with visceral fat reduction, CT scans showed measurable gains in trunk muscle density and lean muscle area over 26 weeks. Therefore, if visceral fat or poor muscle quality is part of your profile, the compound is studied for its potential to shift the balance toward tissue-level repair signals instead of only lowering fat mass.\n\nStep 1: GH release increases. Step 2: IGF-1 rises in a pulsatile way. Step 3: Muscle protein turnover favors synthesis. Step 4: In responders, muscle fat decreases and lean area increases on imaging. This targets the regenerative side of the equation for the layers listed above.\n\n## How these fit together\nSingle-compound focus. Tesamorelin maps directly to the GH axis and visceral fat layer. If your situation includes multiple degeneration layers, this agent addresses the endocrine and body-composition component. Other approaches would need separate evaluation for neural, sleep, or direct anabolic layers.\n\n## What the evidence actually shows\nHuman data come from secondary analyses of randomized trials in adults with HIV and abdominal obesity. One key study (Adrian et al.) restricted analysis to tesamorelin responders who lost at least 8% visceral adipose tissue. Compared with placebo, these participants showed statistically significant increases in muscle density (1.56–4.86 Hounsfield units across trunk muscle groups) and lean muscle area (0.64–1.08 cm²). A later meta-analysis reported a mean lean body mass increase of 1.42 kg. An ongoing trial (NCT06554717) is testing tesamorelin plus exercise for physical function in HIV. No large human trials exist for primary sarcopenia in non-HIV populations. Animal data on muscle-specific outcomes with tesamorelin are not prominent in the reviewed sources. Reddit and X reports remain anecdotal.\n\n## What scientists say\nThe authors of the 2019 Journal of Frailty & Aging paper conclude that among responders, tesamorelin increased skeletal muscle area and density. They note the changes occurred alongside visceral fat reduction and call for longer-term studies on functional impact outside HIV. Reviews emphasize that lean mass gains occur without proportional subcutaneous fat loss or major glycemic disruption in the studied cohorts. Researchers highlight that benefits appear tied to visceral fat responders rather than universal.\n\n## What people say on Reddit\nUsers in peptide communities describe tesamorelin as helping preserve lean mass during calorie deficits. One post states: “Tesa is a tool that raises IGF-1 levels which can in turn preserves muscle mass in a calories deficit and potentially build lean muscle.” Another reports: “Even with zero exercise my lean muscle mass increased by about 15%, visceral fat reduction by 80%.” Several mention better recovery and visible muscle definition when combined with training, though scale weight often stays stable because fat loss offsets any lean gain. Experiences vary; some note waist reduction without overall weight change.\n\n## What people say on X\nPublic posts on X referencing tesamorelin and muscle are sparse in current searches. Most discussion echoes the clinical focus on visceral fat reduction and secondary lean mass observations from the HIV trials. Anecdotal functional claims appear less frequently than on Reddit.\n\n## What we do not know\nHuman evidence is concentrated in HIV populations with abdominal obesity. Direct trials in age-related sarcopenia or non-HIV muscle loss are absent. Long-term (>26 weeks) effects on muscle strength, physical performance, or fracture risk remain unmeasured in published data. Whether gains persist after stopping treatment is unknown. Interactions with resistance training protocols or other body-composition interventions need further controlled study. Effects on muscle in women or diverse ethnic groups are underrepresented.\n\n## Safety and limits\nReported adverse events in trials include injection-site reactions, arthralgia, myalgia, and paresthesia. No major glucose dysregulation appeared in the meta-analysis. Human data are limited to specific responder subgroups and short-to-medium durations. Individual responses differ, and imaging changes do not automatically equal improved daily function. All observations come from controlled settings; real-world variability is higher.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin-muscle-loss/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"In a secondary analysis of randomized trials, tesamorelin responders (visceral fat loss ≥8%) showed greater increases in trunk muscle density (1.56–4.86 HU) and lean muscle area (0.64–1.08 cm²) vs placebo after 26 weeks.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Provides direct human imaging evidence linking tesamorelin response to muscle quality changes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Meta-analysis of tesamorelin trials reported a mean lean body mass increase of 1.42 kg alongside visceral fat reduction.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Quantifies lean mass effect across studies in the target population.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"An ongoing clinical trial (NCT06554717) is evaluating tesamorelin plus exercise for physical function and muscle health in adults with HIV.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Indicates active research extending beyond fat loss to function.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report lean mass preservation or modest gains alongside visceral fat loss when using tesamorelin in calorie deficits, often with improved recovery.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4","s5"],"source_status":"sourced","why_material":"Captures real-user perceptions separate from trial data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31237318/","title":"The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV","quote":"tesamorelin was effective in increasing skeletal muscle area and density","summary":"Secondary analysis of two RCTs; CT-based muscle metrics in responders.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.507Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"b0762e1a20bcb7cab143fe210ef8291514be54fde7f370f5f92e0a7c6dd854c0"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"A meta-analysis of randomized controlled trials","quote":"A significant increase in lean body mass was observed (MD=1.42 kg, 95% CI [1.13, 1.71]; P < 0.001)","summary":"Pooled body composition outcomes from tesamorelin trials in HIV lipodystrophy.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.507Z","link_status":"ok","quote_status":"unverified","prev":"b0762e1a20bcb7cab143fe210ef8291514be54fde7f370f5f92e0a7c6dd854c0","hash":"96428706c2883c39545e36d3041e878f23e861dc3101a3979c9723c8946bcb5a"},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06554717","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function and Muscle Health in Adults With HIV","quote":"learn whether the medication tesamorelin will improve physical function and muscle health","summary":"Active trial combining tesamorelin with exercise.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.507Z","link_status":"ok","quote_status":"unverified","prev":"96428706c2883c39545e36d3041e878f23e861dc3101a3979c9723c8946bcb5a","hash":"3efea45c7c0c600b6dafd5b208d79dac941b37d97678691fa9d6c0281bc2e738"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/USPeptides/comments/1p3bh79/tesamorelin_belly_fat_reduction_growth_hormone/","title":"Tesamorelin Belly Fat Reduction","quote":"Tesa is a tool that raises IGF-1 levels which can in turn preserves muscle mass in a calories deficit","summary":"User discussion on muscle preservation.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.507Z","link_status":"ok","quote_status":"unverified","prev":"3efea45c7c0c600b6dafd5b208d79dac941b37d97678691fa9d6c0281bc2e738","hash":"29bc4fe1e1f6416bf82182800cddf3d1d1a998010ac69696096d1fa77afd898a"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1qlnwf7/starting_tesamorelin_next_week_advice_needed/","title":"Starting Tesamorelin","quote":"Even with zero exercise my lean muscle mass increased by about 15%","summary":"Self-reported body composition changes.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.507Z","link_status":"ok","quote_status":"unverified","prev":"29bc4fe1e1f6416bf82182800cddf3d1d1a998010ac69696096d1fa77afd898a","hash":"500a99f3722c7580a8a5679617ef7f79b2f3e68ec2b52837a913d9e8591d5e60"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:19:00.263Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Muscle Loss: Human Evidence on Lean Mass, Muscle Density, and the GH Axis","register":"source_ledger","body":"## What's breaking down\nMuscle loss, or sarcopenia-like decline, often stems from reduced growth hormone (GH) signaling with age or illness. This lowers IGF-1, slowing protein synthesis while catabolic processes continue. Visceral fat accumulation adds mechanical and inflammatory stress that can further impair muscle quality. In HIV-related lipodystrophy, excess abdominal fat pairs with muscle fat infiltration and reduced lean area. Repair pathways lag behind breakdown when GH pulses weaken. Tesamorelin is discussed here because studies examine its effect on the GH axis and downstream tissue changes rather than symptom masking.\n\n## Why Tesamorelin might help you\nIf your muscle loss involves low GH/IGF-1 activity or excess visceral fat, the logic chain runs like this. Tesamorelin stimulates the pituitary to release endogenous GH in a more physiologic pattern. That raises circulating IGF-1. Higher IGF-1 supports protein synthesis in muscle tissue. In people who respond with visceral fat reduction, CT scans showed measurable gains in trunk muscle density and lean muscle area over 26 weeks. Therefore, if visceral fat or poor muscle quality is part of your profile, the compound is studied for its potential to shift the balance toward tissue-level repair signals instead of only lowering fat mass.\n\nStep 1: GH release increases. Step 2: IGF-1 rises in a pulsatile way. Step 3: Muscle protein turnover favors synthesis. Step 4: In responders, muscle fat decreases and lean area increases on imaging. This targets the regenerative side of the equation for the layers listed above.\n\n## How these fit together\nSingle-compound focus. Tesamorelin maps directly to the GH axis and visceral fat layer. If your situation includes multiple degeneration layers, this agent addresses the endocrine and body-composition component. Other approaches would need separate evaluation for neural, sleep, or direct anabolic layers.\n\n## What the evidence actually shows\nHuman data come from secondary analyses of randomized trials in adults with HIV and abdominal obesity. One key study (Adrian et al.) restricted analysis to tesamorelin responders who lost at least 8% visceral adipose tissue. Compared with placebo, these participants showed statistically significant increases in muscle density (1.56–4.86 Hounsfield units across trunk muscle groups) and lean muscle area (0.64–1.08 cm²). A later meta-analysis reported a mean lean body mass increase of 1.42 kg. An ongoing trial (NCT06554717) is testing tesamorelin plus exercise for physical function in HIV. No large human trials exist for primary sarcopenia in non-HIV populations. Animal data on muscle-specific outcomes with tesamorelin are not prominent in the reviewed sources. Reddit and X reports remain anecdotal.\n\n## What scientists say\nThe authors of the 2019 Journal of Frailty & Aging paper conclude that among responders, tesamorelin increased skeletal muscle area and density. They note the changes occurred alongside visceral fat reduction and call for longer-term studies on functional impact outside HIV. Reviews emphasize that lean mass gains occur without proportional subcutaneous fat loss or major glycemic disruption in the studied cohorts. Researchers highlight that benefits appear tied to visceral fat responders rather than universal.\n\n## What people say on Reddit\nUsers in peptide communities describe tesamorelin as helping preserve lean mass during calorie deficits. One post states: “Tesa is a tool that raises IGF-1 levels which can in turn preserves muscle mass in a calories deficit and potentially build lean muscle.” Another reports: “Even with zero exercise my lean muscle mass increased by about 15%, visceral fat reduction by 80%.” Several mention better recovery and visible muscle definition when combined with training, though scale weight often stays stable because fat loss offsets any lean gain. Experiences vary; some note waist reduction without overall weight change.\n\n## What people say on X\nPublic posts on X referencing tesamorelin and muscle are sparse in current searches. Most discussion echoes the clinical focus on visceral fat reduction and secondary lean mass observations from the HIV trials. Anecdotal functional claims appear less frequently than on Reddit.\n\n## What we do not know\nHuman evidence is concentrated in HIV populations with abdominal obesity. Direct trials in age-related sarcopenia or non-HIV muscle loss are absent. Long-term (>26 weeks) effects on muscle strength, physical performance, or fracture risk remain unmeasured in published data. Whether gains persist after stopping treatment is unknown. Interactions with resistance training protocols or other body-composition interventions need further controlled study. Effects on muscle in women or diverse ethnic groups are underrepresented.\n\n## Safety and limits\nReported adverse events in trials include injection-site reactions, arthralgia, myalgia, and paresthesia. No major glucose dysregulation appeared in the meta-analysis. Human data are limited to specific responder subgroups and short-to-medium durations. Individual responses differ, and imaging changes do not automatically equal improved daily function. All observations come from controlled settings; real-world variability is higher.","claims":[{"id":"c1","text":"In a secondary analysis of randomized trials, tesamorelin responders (visceral fat loss ≥8%) showed greater increases in trunk muscle density (1.56–4.86 HU) and lean muscle area (0.64–1.08 cm²) vs placebo after 26 weeks.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Provides direct human imaging evidence linking tesamorelin response to muscle quality changes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Meta-analysis of tesamorelin trials reported a mean lean body mass increase of 1.42 kg alongside visceral fat reduction.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Quantifies lean mass effect across studies in the target population.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"An ongoing clinical trial (NCT06554717) is evaluating tesamorelin plus exercise for physical function and muscle health in adults with HIV.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Indicates active research extending beyond fat loss to function.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report lean mass preservation or modest gains alongside visceral fat loss when using tesamorelin in calorie deficits, often with improved recovery.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4","s5"],"source_status":"sourced","why_material":"Captures real-user perceptions separate from trial data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.891Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31237318/","title":"The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV","quote":"tesamorelin was effective in increasing skeletal muscle area and density","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"A meta-analysis of randomized controlled trials","quote":"A significant increase in lean body mass was observed (MD=1.42 kg, 95% CI [1.13, 1.71]; P < 0.001)","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06554717","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function and Muscle Health in Adults With HIV","quote":"learn whether the medication tesamorelin will improve physical function and muscle health","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/USPeptides/comments/1p3bh79/tesamorelin_belly_fat_reduction_growth_hormone/","title":"Tesamorelin Belly Fat Reduction","quote":"Tesa is a tool that raises IGF-1 levels which can in turn preserves muscle mass in a calories deficit","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1qlnwf7/starting_tesamorelin_next_week_advice_needed/","title":"Starting Tesamorelin","quote":"Even with zero exercise my lean muscle mass increased by about 15%","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":28916,"tokens_out":3094,"cost":0.04388,"prev_hash":"genesis","hash":"d531986ced9cab26dc5f9ff393cb4ce2acdedea1998974b4ef45145e7f6e6c8f"}],"provenance":[{"ts":"2026-06-29T23:19:00.263Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Muscle Loss\nSlug: tesamorelin-muscle-loss\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down\",\"Why Tesamorelin might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one pept","response":"{\n  \"slug\": \"tesamorelin-muscle-loss\",\n  \"title\": \"Tesamorelin for Muscle Loss: Human Evidence on Lean Mass, Muscle Density, and the GH Axis\",\n  \"body\": \"## What's breaking down\\nMuscle loss, or sarcopenia-like decline, often stems from reduced growth hormone (GH) signaling with age or illness. This lowers IGF-1, slowing protein synthesis while catabolic processes continue. Visceral fat accumulation adds mechanical and inflammatory stress that can further impair muscle quality. In HIV-related lipodystrophy, excess abdominal fat pairs with muscle fat infiltration and reduced lean area. Repair pathways lag behind breakdown when GH pulses weaken. Tesamorelin is discussed here because studies examine its effect on the GH axis and downstream tissue changes rather than symptom masking.\\n\\n## Why Tesamorelin might help you\\nIf your muscle loss involves low GH/IGF-1 activity or excess visceral fat, the logic chain runs like this. Tesamorelin stimulates the pituitary to release endogenous GH in a more physiologic pattern. That raises circulating IGF-1. Higher IGF-1 supports protein synthesis in muscle tissue. In people who respond with visceral fat reduction, CT scans showed measurable gains in trunk muscle density and lean muscle area over 26 weeks. Therefore, if visceral fat or poor muscle quality is part of your profile, the compound is studied for its potential to shift the balance toward tissue-level repair signals instead of only lowering fat mass.\\n\\nStep 1: GH release increases. Step 2: IGF-1 rises in a pulsatile way. Step 3: Muscle protein turnover favors synthesis. Step 4: In responders, muscle fat decreases and lean area increases on imaging. This targets the regenerative side of the equation for the layers listed above.\\n\\n## How these fit together\\nSingle-compound focus. Tesamorelin maps directly to the GH axis and visceral fat layer. If your situation includes multiple degeneration layers, this agent addresses the endocrine and body-composition component. Other","tokens_in":28916,"tokens_out":3094,"cost":0,"prev":"genesis","hash":"b893f8d91bcfbfd430c532f9f3d2c122415b4396cf0188fe404dfd7fcdea664f"},{"ts":"2026-07-17T02:42:24.087Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-muscle-loss","response":"19 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b893f8d91bcfbfd430c532f9f3d2c122415b4396cf0188fe404dfd7fcdea664f","hash":"19fbfa92b36bdaf0eb9f55164dc454f801ea701aad9e0d7c424975e61ff55919"}],"energy":{"passes":2,"tokens_in":28916,"tokens_out":3094,"tokens_total":32010,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"19fbfa92b36bdaf0eb9f55164dc454f801ea701aad9e0d7c424975e61ff55919"},"posted_at":"2026-06-29T21:33:33.546Z","created_at":"2026-06-29T21:33:33.546Z","updated_at":"2026-07-17T02:42:24.087Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin-muscle-loss","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin-muscle-loss","json":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss","bundle":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin-muscle-loss","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-muscle-loss\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-muscle-loss\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin-muscle-loss\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin-muscle-loss | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin-muscle-loss","json":"/api/articles/tesamorelin-muscle-loss","markdown":"/api/articles/tesamorelin-muscle-loss/bundle?format=markdown","skill":"/api/articles/tesamorelin-muscle-loss/skill","topology":"/api/articles/tesamorelin-muscle-loss/topology","versions":"/api/articles/tesamorelin-muscle-loss/revisions","invocations":"/api/articles/tesamorelin-muscle-loss/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin-muscle-loss","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"1fc7c99e0fb6ccfb9e96473b3ca8696008fab4fc7b0ebc642ebeaa71097037f0"}}}